Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial : The Lancet
The Lancet - Early Online Publication, 10/22/2010
Gane EJ et al. – This oral combination of a nucleoside analogue polymerase inhibitor and protease inhibitor holds promise as an interferon–free treatment for chronic hepatitis C virus.



